4D-150
Wet Age-Related Macular Degeneration
Key Facts
About 4D Molecular Therapeutics
4D Molecular Therapeutics is a platform-driven gene therapy company leveraging its proprietary Therapeutic Vector Evolution (TVE) platform to engineer optimized AAV vectors for specific diseases. The company has advanced two lead programs into Phase 3 for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), demonstrating significant reductions in treatment burden, and has a Phase 1/2 program in cystic fibrosis. Its strategy focuses on large markets with high unmet need, validated by strategic partnerships with Astellas and Otsuka, and funding from the Cystic Fibrosis Foundation.
View full company profileAbout 4D Molecular Therapeutics
4D Molecular Therapeutics is a platform-driven gene therapy company leveraging its proprietary Therapeutic Vector Evolution (TVE) platform to engineer optimized AAV vectors for specific diseases. The company has advanced two lead programs into Phase 3 for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), demonstrating significant reductions in treatment burden, and has a Phase 1/2 program in cystic fibrosis. Its strategy focuses on large markets with high unmet need, validated by strategic partnerships with Astellas and Otsuka, and funding from the Cystic Fibrosis Foundation.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Wet AMD Program | Exonate | Pre-clinical |
| AKST4290 | Alkahest | Phase 2 |
| AXPAXLI (OTX-TKI) | Ocular Therapeutix | NDA Submitted |